Entrada Therapeutics (Nasdaq: TRDA) granted 18,600 restricted stock units (RSUs) to three newly hired non-executive employees under its 2025 Inducement Equity Plan, effective June 1, 2026.
The RSUs vest 25% after one year, then 6.25% quarterly, subject to continued service.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
Key Figures
RSUs granted:18,600 RSUsInitial vesting:25% of RSUsOngoing vesting rate:6.25% quarterly+3 more
6 metrics
RSUs granted18,600 RSUsAggregate inducement grants to three newly hired non‑executive employees
Initial vesting25% of RSUsVests on the one‑year anniversary of the vesting commencement date
Ongoing vesting rate6.25% quarterlyVests each March 1, June 1, September 1, December 1 after first year
Grant effective dateJune 1, 2026Effective date for inducement RSU awards under the 2025 Inducement Plan
Plan approval dateMarch 20252025 Inducement Equity Plan approval by Board of Directors
VolumeVolume 280,027 is below the 20-day average of 717,276 (relative volume 0.39x), suggesting limited trading interest ahead of this minor HR update.low
TechnicalShares at $6.91 are trading below the 200-day moving average of $9.37 and remain 57.99% under the 52-week high of $16.45 while sitting 40.16% above the 52-week low of $4.93.
Peers on Argus
TRDA gained 3.67% with subdued volume while peers showed mixed performance: CGTX...
1 Up
TRDA gained 3.67% with subdued volume while peers showed mixed performance: CGTX rose 6.84%, CCCC inched up 0.69%, and EPRX and TNYA declined 5.12% and 3.92%, respectively. Only TNYA appeared in the momentum scanner, reinforcing a stock-specific backdrop for TRDA.
Common CatalystOne peer, CGTX, reported conference participation, but there is no broad, shared catalyst across the biotechnology peer set tied to TRDA’s HR-related announcement.
Reported FY 2025 results and advanced multiple DMD and USH2A programs.
Pattern Detected
Recent history shows large negative reactions (around -57%) even to positive clinical and earnings updates, alongside smaller, more typical moves on routine items like inducement grants and regular earnings.
Recent Company History
Over the last few months, Entrada reported multiple clinical and financial milestones. On Feb 26, 2026, it posted Q4 and full‑year 2025 results with $295.7 million in cash and a full‑year net loss of $143.8 million, and the stock rose 6.76%. In early May 2026, positive Phase 1/2 ENTR‑601‑44 data and Q1 2026 results coincided with a sharp -57.27% move, showing a pronounced divergence between strong scientific updates and share performance. Prior inducement grants on Mar 2, 2026 saw only a modest 1.46% reaction.
Regulatory & Risk Context
Active S-3 Shelf · $400,000,000
Shelf Active
Active S-3 Shelf Registration
2025-11-06
$400,000,000registered capacity
Entrada filed a Form S-3 shelf registration on Nov 06, 2025 to offer up to $400,000,000 of securities, including a $150,000,000 ATM program within that total. As of the latest context, the shelf is not effective, with 0 recorded usages and no recent 424B prospectus supplements.
Market Pulse Summary
This announcement details routine hiring-related equity awards: 18,600 RSUs for three new non‑execut...
Analysis
This announcement details routine hiring-related equity awards: 18,600 RSUs for three new non‑executive employees under the 2025 Inducement Equity Plan, vesting 25% after one year and 6.25% quarterly thereafter. It follows a period marked by significant clinical data releases and earnings reports. Investors tracking TRDA may focus more on upcoming Duchenne muscular dystrophy readouts, cash runway disclosures, and any future use of the existing $400,000,000 shelf registration.
Key Terms
restricted stock units, nasdaq listing rule 5635(c)(4), inducement equity plan
3 terms
restricted stock unitsfinancial
"granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement equity planfinancial
"under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”)"
An inducement equity plan is a program that offers employees or executives new stock options or shares as a way to encourage them to join or stay with a company. It acts like a reward or incentive to motivate performance and loyalty, aligning their interests with the company's success. For investors, such plans can influence a company's share structure and future earnings, making them an important factor to consider.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units (“RSUs”) to three newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest quarterly thereafter on each subsequent vesting date, with such vesting dates of March 1, June 1, September 1 and December 1 of each subsequent year, in each case, subject to each employee’s continuous service with the Company through each vesting date. The RSUs are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2025 and the terms and conditions of award agreements covering the grants.
About Entrada Therapeutics Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
What inducement equity grants did Entrada Therapeutics (TRDA) announce on June 1, 2026?
Entrada Therapeutics granted an aggregate of 18,600 restricted stock units to three newly hired non-executive employees. According to Entrada Therapeutics, these awards were made under its 2025 Inducement Equity Plan as a material inducement to the employees’ entry into employment.
How many RSUs did each new Entrada Therapeutics (TRDA) employee receive in June 2026?
Entrada Therapeutics granted a total of 18,600 RSUs to three new non-executive employees, but individual allocations were not disclosed. According to Entrada Therapeutics, the grants were made in aggregate under the 2025 Inducement Equity Plan as employment inducements.
What is the vesting schedule for the June 1, 2026 Entrada Therapeutics (TRDA) RSU grants?
The RSUs vest 25% on the one-year anniversary of the vesting commencement date, then 6.25% quarterly. According to Entrada Therapeutics, vesting dates fall on March 1, June 1, September 1 and December 1, subject to each employee’s continuous service.
Under which plan were the June 2026 Entrada Therapeutics (TRDA) inducement RSUs granted?
The RSUs were granted under Entrada Therapeutics’ 2025 Inducement Equity Plan. According to Entrada Therapeutics, the plan was approved by the board of directors in March 2025 and is used for Nasdaq Listing Rule 5635(c)(4) compliant inducement awards.
Why did Entrada Therapeutics (TRDA) use Nasdaq Listing Rule 5635(c)(4) for these RSU grants?
Entrada Therapeutics used Nasdaq Listing Rule 5635(c)(4) because the RSUs serve as a material inducement to new employees. According to Entrada Therapeutics, the Compensation Committee approved these awards specifically to support employee recruitment under this Nasdaq rule.
What conditions must employees meet to receive full vesting of Entrada Therapeutics (TRDA) June 2026 RSUs?
Employees must maintain continuous service with Entrada Therapeutics through each vesting date to receive the RSUs. According to Entrada Therapeutics, vesting occurs over time, beginning one year after the vesting commencement date and continuing quarterly at 6.25% thereafter.
